resTORbio (TORC) Stock Rating Lowered by Zacks Investment Research
resTORbio (NASDAQ:TORC) was downgraded by Zacks Investment Research from a “hold” rating to a “sell” rating in a report issued on Thursday.
According to Zacks, “resTORbio, Inc. is a clinical-stage biopharmaceutical company. It focused on the development and commercialization of therapeutics for the treatment of aging-related diseases. The company’s program consists of rapamycin complex 1 pathway to treat aging-related diseases and conditions. Its lead product candidate, RTB101 is an orally administered, small molecule, potent TORC1 inhibitor which is in clinical stage. resTORbio, Inc. is based in BOSTON, United States. “
Separately, Evercore ISI reissued an “in-line” rating on shares of resTORbio in a report on Wednesday, August 1st. One research analyst has rated the stock with a sell rating, two have issued a hold rating and three have issued a buy rating to the company’s stock. The company presently has a consensus rating of “Hold” and an average price target of $26.60.
resTORbio (NASDAQ:TORC) last released its quarterly earnings results on Thursday, August 9th. The company reported ($0.48) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.42) by ($0.06). Equities research analysts anticipate that resTORbio will post -1.86 EPS for the current year.
A number of institutional investors have recently added to or reduced their stakes in the stock. Bank of New York Mellon Corp increased its stake in resTORbio by 76.7% in the second quarter. Bank of New York Mellon Corp now owns 21,693 shares of the company’s stock valued at $199,000 after purchasing an additional 9,413 shares during the last quarter. SCP Investment LP acquired a new position in resTORbio in the second quarter valued at $893,000. BlackRock Inc. increased its stake in resTORbio by 7.4% in the second quarter. BlackRock Inc. now owns 320,310 shares of the company’s stock valued at $2,930,000 after purchasing an additional 22,169 shares during the last quarter. Deltec Asset Management LLC acquired a new position in resTORbio in the second quarter valued at $2,509,000. Finally, Wedbush Securities Inc. acquired a new position in resTORbio in the second quarter valued at $236,000. Hedge funds and other institutional investors own 42.33% of the company’s stock.
resTORbio, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for the treatment of aging-related diseases. Its lead program is targeting the selective inhibition of TORC1, an evolutionary conserved pathway that contributes to the decline in function of multiple organ systems, including the immune, cardiac, and neurologic systems.
See Also: Google Finance Portfolio Tips and Tricks
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for resTORbio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for resTORbio and related companies with MarketBeat.com's FREE daily email newsletter.